2013
DOI: 10.1016/j.ijantimicag.2013.04.033
|View full text |Cite
|
Sign up to set email alerts
|

Antibacterial activity of head-to-head bis-benzimidazoles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
16
0
1

Year Published

2015
2015
2022
2022

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 31 publications
(19 citation statements)
references
References 13 publications
2
16
0
1
Order By: Relevance
“…Several bis-benzimidazoles have shown significant antibacterial activities against drug-resistant bacteria (methicillin-resistant Staphylococcus aureus -MRSA and methicillin resistant S. epidermidis -MRSE and vancomycin resistant enterococci -VRE strains) [19,37]. In addition, diamidine derivatives of bis-indoles, as structural analogues of benzimidazoles, were shown to exhibit in vitro activity against a broad spectrum of Gramnegative and Gram-positive pathogens such as S. aureus (including MRSA) and E. faecalis (including VRE) which additionally supports the use of mono-and bis-benzimidazole units in 3,4-ethylenedioxythiophene series [21,24].…”
Section: Introductionmentioning
confidence: 99%
“…Several bis-benzimidazoles have shown significant antibacterial activities against drug-resistant bacteria (methicillin-resistant Staphylococcus aureus -MRSA and methicillin resistant S. epidermidis -MRSE and vancomycin resistant enterococci -VRE strains) [19,37]. In addition, diamidine derivatives of bis-indoles, as structural analogues of benzimidazoles, were shown to exhibit in vitro activity against a broad spectrum of Gramnegative and Gram-positive pathogens such as S. aureus (including MRSA) and E. faecalis (including VRE) which additionally supports the use of mono-and bis-benzimidazole units in 3,4-ethylenedioxythiophene series [21,24].…”
Section: Introductionmentioning
confidence: 99%
“…A graduate student on the Royal Pharmaceutical Society award, Joao Moreira, profiled 21 symmetric and asymmetric BBZs against a comprehensive panel of Gram-positive clinical isolates, including ten from the initial series synthesised by John Mann and co-workers. This in-depth study 23 confirmed the lack of activity against a wide range of Gram-negative pathogens but established that three compounds in particular possessed potent anti-staphylococcal activity against four methicillin-susceptible S. aureus and 61 MRSA strains from Peter Taylor's extensive international collection of clinical isolates, with clinically attractive MIC 90 values (MIC required to inhibit 90% of the isolates) in the sub-μg ml –1 range. Similar potent effects were recorded against vancomycin intermediate-susceptible S. aureus (VISA; clinically troublesome MRSA partially resistant to the drug of last resort), Streptococcus pyogenes , Streptococcus agalactiae and β-haemolytoc streptococci.…”
Section: Microbiological Studiesmentioning
confidence: 69%
“…Compounds 26c and 26d exhibited significant activity against M. tuberculosis H37Rv with MIC value of 2 mg/L and 1 mg/L, respectively (Fig. 6) [34].…”
Section: Biological Profilementioning
confidence: 99%